ZGNX Zogenix Inc.

48.96
+1.1  (+2%)
Previous Close 47.86
Open 48.36
Price To Book 3.81
Market Cap 2054754210
Shares 41,968,019
Volume 329,711
Short Ratio
Av. Daily Volume 503,769

NewsSee all news

  1. Zogenix to Release Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on February 28
  2. Zogenix to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  3. How an East Bay drug maker pivoted from opioids to the cusp of a seizure drug approval
  4. Zogenix Submits New Drug Application to U.S. Food & Drug Administration and Marketing Authorization Application to European Medicines Agency for FINTEPLA® for the Treatment of Dravet Syndrome
  5. Are Insiders Selling Zogenix, Inc. (NASDAQ:ZGNX) Stock?

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19608208
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606768
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19597172
  4. 8-K - Current report 19591016
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19582308

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced November 29, 2017.
ZX008
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Completion of rolling NDA submission announced February 6, 2019.
FINTEPLA (ZX008)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. Zogenix to Release Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on February 28
  2. Zogenix to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  3. How an East Bay drug maker pivoted from opioids to the cusp of a seizure drug approval
  4. Zogenix Submits New Drug Application to U.S. Food & Drug Administration and Marketing Authorization Application to European Medicines Agency for FINTEPLA® for the Treatment of Dravet Syndrome
  5. Are Insiders Selling Zogenix, Inc. (NASDAQ:ZGNX) Stock?
  6. Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  7. Detailed Research: Economic Perspectives on Advanced Micro Devices, Blackbaud, United States Cellular, CalAmp, Visteon, and Zogenix — What Drives Growth in Today's Competitive Landscape
  8. Edited Transcript of ZGNX earnings conference call or presentation 8-Nov-18 9:30pm GMT
  9. Is Zogenix, Inc.’s (NASDAQ:ZGNX) CEO Salary Justified?
  10. JPMorgan Thinks This Pot Stock Is a "Clear Leader"
  11. Eversept Partners’ Return, AUM, and Holdings
  12. New Research: Key Drivers of Growth for Ashland Global, Intellia Therapeutics, Thor Industries, Zogenix, BWX Technologies, and Heidrick & Struggles International — Factors of Influence, Major Initiatives and Sustained Production
  13. Here is What Hedge Funds Think About Zogenix, Inc. (ZGNX)
  14. Final trades: Home Depot, Target, Charter Communications,...
  15. What Kind Of Share Price Volatility Should You Expect For Zogenix Inc (NASDAQ:ZGNX)?
  16. Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
  17. Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome
  18. Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2018 Annual Meeting

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19608208
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606768
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19597172
  4. 8-K - Current report 19591016
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19582308
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 19578863
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19572579
  8. 8-K - Current report 19569888
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 19562680
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19520381